CYP2C8 and breast carcinoma: A lower paclitaxel clearance has been demonstrated in CYP2C8*3 carrier patients with ovarian cancer than in non-carriers [34], and in contrast, increased paclitaxel-metabolizing activity was attributed to CYP2C8*3 allele in breast cancer patients [35].